Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardiovascular

Set Alert for Cardiovascular

Acceleron Investors Want Merck To Pay More, Ask Company To Wait For Better Offer

Avoro Capital, Holocene Advisors and Darwin Global say that Acceleron should sell later for a higher price based on forthcoming data or Merck should raise its bid above $180 per share.

Deals M & A

Q3 Review: Editor’s Picks Of Scrip's Top Stories

From the latest COVID-19 advances to the emergence of a game changer for heart failure, Scrip’s editor in chief Eleanor Malone reviews the big stories of the past three months. Safety issues around JAK inhibitors and AAV vector-based gene therapy were also to the fore, while biopharma financing continued apace.

Commercial Companies

Merck’s $11.5bn Acceleron Buy Partially Fills Future Keytruda Revenue Gap

The company announced the biggest biopharma M&A deal of the year so far, but Merck will need more large deals to manage declining sales when its top-selling product faces biosimilars in 2028. 

Deals M & A

Lexeo Raises $100m To Advance CNS Candidates, Validate Cardiac Gene Therapies

The company, which has treatments in the clinic for CLN2 Batten disease and APOE4-associated Alzheimer’s disease, is developing AAV-mediated gene therapies designed for safer outcomes.

Financing Gene Therapy

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: new US warnings for JAK inhibitors; strong new heart failure results for Jardiance; good head-to-head results for Pfizer in atopic dermatitis; US payers and drug exclusion lists; and a look ahead at key expected hematology launches.

Biologics Research & Development

Empire Building: Jardiance To Take ‘Special Place’ In Heart Failure

Boehringer Ingelheim’s cardiometabolism head Mohamed Eid considers the impact of EMPEROR-Preserved study on the heart failure treatment landscape and looks ahead at potential new conquests in kidney disease for its SGLT2 inhibitor.

Cardiovascular Clinical Trials

All Systems Go For Novartis 'World-First' Leqvio Pact With England

A price has finally been agreed for Novartis's small interfering RNA therapy and over the next three years, NHS England now expects to treat about 300,000 patients at high risk of a second cardiovascular event with inclisiran.

Cardiovascular Market Access

BI/Lilly's Jardiance Crowned As Heart Failure Game Changer After EMPEROR-Preserved

The full dataset from the closely-watched study demonstrated that Jardiance showed a 21% reduction in the risk of cardiovascular death or hospitalization for HFpEF compared with placebo, a significantly greater benefit than seen with the only approved drug for the indication, Novartis's Entresto.

Clinical Trials Research & Development

Cardior Counts On RNA To Tackle Cardiac Disease

The German firm intends to use the proceeds from an over-subscribed round to move its micro-RNA-132 inhibitor forward into trials for heart failure and advance its pipeline.

Cardiovascular Financing

An EpiPen For Heart Attacks? Idorsia Launches Phase III Study Of Selatogrel

Jean-Paul Clozel, whose firm Actelion was bought by Johnson & Johnson for $30bn, is back with his new company and a new approach to help save the lives of heart attack patients.

Clinical Trials Commercial

BI/Lilly's Jardiance Enters US Heart Failure Market Fray

Boehringer Ingelheim and Eli Lilly have gained a US approval for their SGLT2 inhibitor empagliflozin in heart failure with reduced ejection fraction, which could be extended further in coming months to other types of heart failure, adding to the products competing in this previously neglected therapeutic area.

Approvals Cardiovascular

Bayer Backs Kerendia To Be A Blockbuster

Just approved In US for chronic kidney disease in patients with type 2 diabetes, Kerendia is going to be an important new treatment option, according to Bayer pharma head Stefan Oelrich, who was speaking as the Leverkusen-headquartered group unveiled a decent set of sales figures for the second quarter.

Sales & Earnings Launches
See All
UsernamePublicRestriction

Register